Crossref journal-article
American Society for Microbiology
Infection and Immunity (235)
Abstract

ABSTRACT The type III secretion (TTS) system is used by several animal and plant pathogens to deliver effector proteins into the cytosol of the eukaryotic target cell as a strategy to evade the defense reactions elicited by the infected organism. The fact that these systems are highly homologous implies that novel antibacterial agents that chemically attenuate the pathogens via a specific interaction with the type III secretion mechanism can be identified. A number of small organic molecules having this potential have recently been identified (A. M. Kauppi, R. Nordfelth, H. Uvell, H. Wolf-Watz, and M. Elofsson, Chem. Biol. 10:241-249, 2003). Using different reporter gene constructs, we showed that compounds that belong to a class of acylated hydrazones of different salicylaldehydes target the TTS system of Yersinia pseudotuberculosis . One of these compounds, compound 1, was studied in detail and was found to specifically block Yop effector secretion under in vitro conditions by targeting the TTS system. In this respect the drug mimics the well-known effect of calcium on Yop secretion. In addition, compound 1 inhibits Yop effector translocation after infection of HeLa cells without affecting the eukaryotic cells or the bacteria. A HeLa cell model that mimics in vivo conditions showed that compound 1 chemically attenuates the pathogen to the advantage of the eukaryotic cell. Thus, our results show proof of concept, i.e., that small compounds targeting the TTS system can be identified, and they point to the possible use of TTS inhibitors as a novel class of antibacterial agents.

Bibliography

Nordfelth, R., Kauppi, A. M., Norberg, H. A., Wolf-Watz, H., & Elofsson, M. (2005). Small-Molecule Inhibitors Specifically Targeting Type III Secretion. Infection and Immunity, 73(5), 3104–3114.

Authors 5
  1. R. Nordfelth (first)
  2. A. M. Kauppi (additional)
  3. H. A. Norberg (additional)
  4. H. Wolf-Watz (additional)
  5. M. Elofsson (additional)
References 52 Referenced 183
  1. 10.1016/S0162-0134(99)00131-2
  2. 10.1016/S0958-1669(00)00155-5
  3. 10.1111/j.1365-2958.1995.mmi_18020343.x
  4. 10.1128/JB.184.5.1287-1295.2002
  5. 10.1186/1471-2180-1-22
  6. 10.1177/35.12.3680931
  7. 10.1073/pnas.0307769101
  8. 10.1128/jb.171.1.254-262.1989
  9. 10.1016/0882-4010(87)90078-7
  10. 10.1038/nrm932
  11. 10.1146/annurev.micro.54.1.735
  12. 10.1046/j.1365-2958.1997.2731623.x
  13. 10.1016/0040-4039(95)00138-3
  14. Forsberg, A., and R. Rosqvist. 1993. In vivo expression of virulence genes of Yersinia pseudotuberculosis. Infect. Agents Dis.2:275-278. / Infect. Agents Dis. (1993)
  15. 10.1111/j.1365-2958.1991.tb00773.x
  16. 10.1111/j.1365-2958.1988.tb00013.x
  17. 10.1016/0378-1119(86)90358-6
  18. 10.1056/NEJM199709043371004
  19. 10.1128/mmbr.61.4.393-410.1997
  20. 10.1128/iai.63.2.729-732.1995
  21. 10.1002/j.1460-2075.1996.tb00968.x
  22. 10.1073/pnas.85.6.1749
  23. 10.1046/j.1365-2958.1997.3211681.x
  24. 10.1128/MMBR.62.2.379-433.1998
  25. 10.1001/jama.283.17.2281
  26. Kauppi, A. M., R. Nordfelth, U. Hagglund, H. Wolf-Watz, and M. Elofsson. 2003. Salicylanilides are potent inhibitors of type III secretion in Yersinia. Adv. Exp. Med. Biol.529:97-100. / Adv. Exp. Med. Biol. (2003)
  27. 10.1016/S1074-5521(03)00046-2
  28. Knappik, A., and A. Pluckthun. 1994. An improved affinity tag based on the FLAG peptide for the detection and purification of recombinant antibody fragments. BioTechniques17:754-761. / BioTechniques (1994)
  29. 10.1016/j.coph.2003.04.001
  30. 10.1021/ol0268337
  31. 10.1038/nrmicro798
  32. 10.1517/14728222.5.3.327
  33. 10.1046/j.1365-2958.1999.01537.x
  34. 10.1021/jm980410m
  35. 10.1128/IAI.69.5.3516-3518.2001
  36. 10.1111/j.1365-2958.1995.mmi_18010135.x
  37. 10.1126/science.273.5279.1231
  38. 10.1016/S1369-5274(00)00242-3
  39. 10.1128/jb.174.10.3355-3363.1992
  40. 10.1128/iai.56.8.2139-2143.1988
  41. 10.1111/j.1365-2958.1990.tb00635.x
  42. 10.1002/j.1460-2075.1995.tb00092.x
  43. 10.1002/j.1460-2075.1994.tb06341.x
  44. 10.1016/0882-4010(86)90047-1
  45. 10.1016/j.tim.2004.07.004
  46. 10.1128/jb.175.11.3520-3528.1993
  47. 10.1046/j.1365-2958.2003.03481.x
  48. 10.1038/nrmicro727
  49. 10.1139/v03-183
  50. 10.1046/j.1462-5822.2002.00205.x
  51. 10.1038/nrmicro730
  52. 10.1128/jb.165.2.443-447.1986
Dates
Type When
Created 20 years, 4 months ago (April 20, 2005, 9:03 p.m.)
Deposited 3 years, 5 months ago (March 5, 2022, 12:48 a.m.)
Indexed 4 months, 1 week ago (April 19, 2025, 7:47 a.m.)
Issued 20 years, 3 months ago (May 1, 2005)
Published 20 years, 3 months ago (May 1, 2005)
Published Print 20 years, 3 months ago (May 1, 2005)
Funders 0

None

@article{Nordfelth_2005, title={Small-Molecule Inhibitors Specifically Targeting Type III Secretion}, volume={73}, ISSN={1098-5522}, url={http://dx.doi.org/10.1128/iai.73.5.3104-3114.2005}, DOI={10.1128/iai.73.5.3104-3114.2005}, number={5}, journal={Infection and Immunity}, publisher={American Society for Microbiology}, author={Nordfelth, R. and Kauppi, A. M. and Norberg, H. A. and Wolf-Watz, H. and Elofsson, M.}, year={2005}, month=may, pages={3104–3114} }